TGFB1 and sialadenitis: The EVs from young but not aging HiPSCs-MSCs could reduce sialadenitis onset through decreasing the secretion of Th1 and Th17 cytokines and increasing the secretion of TGF-β1. Further research identified TGF-β1 and miR-21 as positive anti-inflammatory regulators and miR-125b as a negative regulator, which was proved by the fact that the therapeutic effects were restored by inhibiting miR-125b in aging MSCs.